No­var­tis' ap­proved sick­le cell dis­ease drug fails to beat place­bo in PhI­II

No­var­tis’ sick­le cell drug, ap­proved in 2019 and brand­ed as Adakveo, has failed an on­go­ing Phase III, ac­cord­ing to pre­lim­i­nary re­sults.

The Swiss phar­ma gi­ant un­veiled ear­ly da­ta from the on­go­ing STAND Phase III study on Fri­day, say­ing that crizan­l­izum­ab showed no sta­tis­ti­cal­ly sig­nif­i­cant dif­fer­ence be­tween the drug at two dif­fer­ent dose lev­els com­pared to place­bo in an­nu­al­ized rates of va­so-oc­clu­sive crises that lead to a health­care vis­it over the first year since be­ing ran­dom­ized in­to the tri­al.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER